Next Article in Journal
Hierarchical Virtual Screening of Potential Insectides Inhibitors of Acetylcholinesterase and Juvenile Hormone from Temephos
Previous Article in Journal
Insights into the Molecular Mechanisms of Eg5 Inhibition by (+)-Morelloflavone
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2019, 12(2), 60; https://doi.org/10.3390/ph12020060

Late Neurological Consequences of Zika Virus Infection: Risk Factors and Pharmaceutical Approaches

1
School of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro 21944-590, Brazil
2
Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro 21944-590, Brazil
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Received: 1 March 2019 / Revised: 15 March 2019 / Accepted: 17 March 2019 / Published: 17 April 2019
(This article belongs to the Special Issue Zika Virus: Therapeutic Advances)
  |  
PDF [654 KB, uploaded 17 April 2019]
  |     |  

Abstract

Zika virus (ZIKV) infection was historically considered a disease with mild symptoms and no major consequences to human health. However, several long-term, late onset, and chronic neurological complications, both in congenitally-exposed babies and in adult patients, have been reported after ZIKV infection, especially after the 2015 epidemics in the American continent. The development or severity of these conditions cannot be fully predicted, but it is possible that genetic, epigenetic, and environmental factors may contribute to determine ZIKV infection outcomes. This reinforces the importance that individuals exposed to ZIKV are submitted to long-term clinical surveillance and highlights the urgent need for the development of therapeutic approaches to reduce or eliminate the neurological burden of infection. Here, we review the epidemiology of ZIKV-associated neurological complications and the role of factors that may influence disease outcome. Moreover, we discuss experimental and clinical evidence of drugs that have shown promising results in vitro or in vitro against viral replication and and/or ZIKV-induced neurotoxicity. View Full-Text
Keywords: microcephaly; arbovirus; flavivirus; drug development; neurodevelopment; therapy; drug screening; pregnancy; Food and Drug Administration (FDA); encephalitis microcephaly; arbovirus; flavivirus; drug development; neurodevelopment; therapy; drug screening; pregnancy; Food and Drug Administration (FDA); encephalitis
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Souza, I.N.O.; Barros-Aragão, F.G.Q.; Frost, P.S.; Figueiredo, C.P.; Clarke, J.R. Late Neurological Consequences of Zika Virus Infection: Risk Factors and Pharmaceutical Approaches. Pharmaceuticals 2019, 12, 60.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top